Back in 2007, an Alzheimer’s disease candidate called Alzhemed missed its endpoint in a large-scale pivotal study, just one of many late-stage failures in the space, along with Myriad Genetics Inc.’s Flurizan, Medivation Inc.’s Dimebon, Eli Lilly and Co.’s semagacestat and bapineuzumab from Pfizer Inc. and Johnson & Johnson/Eland Corp. plc. (See BioWorld Today, Aug. 28, 2007.)
But Alzhemed, also known as tramiprosate, offered a glimmer of hope.
Despite falling short of the primary endpoint, which measured disease modification using magnetic resonance imaging and clinical efficacy using the Alzheimer’s Disease Assessment Scale, cognitive subpart and Dementia Rating scale, the drug displayed some positive trends, including data suggesting a pharmacological effect on spinal fluid levels of amyloid-beta and tau biomarkers, along with changes in hippocampal volume. Those trends were enough to convince developer Neurochem Inc., which